The Week in Review: Two Major IPOs Announced for China Life Science

Sihuan Pharma filed to IPO in Hong Kong, with the goal of raising $600-$700 million; ShangPharma, a large Shanghai CRO, will stage a $90 million IPO on the NYSE; China’s drug sales will grow 25% in 2011 to over $50 billion, according to IMS Health; BMI predicts China’s pharma market will grow at a CAGR of 13.7% in 2010-14; Tianjin Tasly Pharma in-licensed China rights to ProteoTech’s Alzheimer’s drug; and China researchers are collaborating with UK scientists to improve artemisinin, a TCM widely used to treat malaria. More details…. Stock Symbols: (NYSE: IMS) (SHEX: 600535)